Transgene

Transgene Current Assets

The Current Assets of Transgene (TNG.PA) as of Oct 8, 2026 is 20.67 M EUR. In the previous year, Current Assets was 17.98 M EUR — a change of 14.92% (higher).

Current Assets

20.67 MEUR

YoY

14.92%

Last updated:

Current Assets of Transgene is 2024 20.67 M EUR. Current Assets of Transgene was 2023 17.98 M EUR. It decreases by 14.92% higher compared to the previous year.

The Transgene Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
58.74 M EUR
Jan 1, 2018
29.75 M EUR
Jan 1, 2019
49.64 M EUR
Jan 1, 2020
30.69 M EUR
Jan 1, 2021
62.25 M EUR
Jan 1, 2022
46.51 M EUR
Jan 1, 2023
17.98 M EUR
Jan 1, 2024
20.67 M EUR
The Transgene Current Assets history
YEARCurrent AssetsYoY
20.67 MEUR+14.92%
17.98 MEUR-61.33%
46.51 MEUR-25.29%
62.25 MEUR+102.84%
30.69 MEUR-38.18%
49.64 MEUR+66.83%
29.75 MEUR-49.34%
58.74 MEUR-20.69%
74.06 MEUR+45.13%
51.03 MEUR-35.60%
79.24 MEUR+28.84%
61.50 MEUR-37.50%
98.40 MEUR-31.57%
143.80 MEUR-22.35%
185.20 MEUR+152.32%
73.40 MEUR-28.32%
102.40 MEUR-11.72%
116.00 MEUR+404.35%
23.00 MEUR-21.23%
29.20 MEUR+68.79%
17.30 MEUR-53.74%
37.40 MEUR-35.18%
57.70 MEUR-23.98%
75.90 MEUR+114.41%
35.40 MEUR-33.46%
53.20 MEUR-25.07%
71.00 MEUR+303.41%
17.60 MEUR-41.53%
30.10 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Current Assets of Transgene is 20.67 M EUR in 2024.

Current Assets of Transgene changed from 17.98 M EUR to 20.67 M EUR, representing a 14.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Transgene since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Transgene historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Transgene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene